Phase Ib Active Immunotherapy Trial (Expansion) With a Combination of Two Chimeric (Trastuzumab-like and Pertuzumab-like) HER-2 B Cell Peptide Vaccine Emulsified in ISA 720 Adjuvant in Patients With Advanced Solid Tumors.

This document provides information about a clinical trial, NCT06414733, which is currently in the recruitment phase. The trial aims to study the side effects and optimal dosage of vaccine therapy for patients with metastatic solid tumors. The trial will use vaccines made from antibodies and peptides combined with tumor cells to stimulate the body's immune response against tumor cells. The trial plans to enroll 42 participants with metastatic or unresectable breast or gastrointestinal cancer, and it is expected to be completed by June 2027. The responsible party for the trial is Pravin T.P Kaumaya from Indiana University. [Extracted from the article]